TY - JOUR
T1 - An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer
AU - Katz, Matthew H.
AU - Takimoto, Shinako
AU - Spivack, Daniel
AU - Moossa, A. R.
AU - Hoffman, Robert M.
AU - Bouvet, Michael
N1 - Funding Information:
This study was supported in part by the Department of Health Services, California Cancer Research Program (97-120B) and US National Cancer Institute Grants P30 CA23100-1851 and R43-89779.
PY - 2004
Y1 - 2004
N2 - In order to investigate the antitumor and antimetastatic efficacy of new chemotherapeutic agents, a novel, red-fluorescent, orthotopic model of pancreatic cancer was constructed in nude mice. MIA-PaCa-2 human pancreatic cancer cells were transduced with red fluorescent protein (RFP) and initially grown subcutaneously. Fluorescent tumor fragments were then transplanted onto the pancreas by surgical orthotopic implantation (SOI), facilitating high-resolution, real-time visualization of tumor and metastatic growth and dissemination in vivo. Tumor growth at the primary site was visible within the first postoperative week, while distant metastasis and the development of ascites became visible over the following week. This MIA-PaCa-2-RFP model produced extensive local disease and metastases to the retroperitoneum (100%), spleen (100%), intestinal and periportal lymph nodes (100%), liver (40%) and diaphragm (80%), and gave rise to malignant ascites and peritoneal carcinomatosis in 80% of cases. Growth and metastasis of tumor was more rapid and frequent than in previously described orthotopic pancreatic cancer models, leading to a median survival of only 21 days after tumor implantation. This unique, red fluorescent model rapidly and reliably simulates the highly aggressive course of human pancreatic cancer and can be easily non-invasively visualized in the live animal. The model can therefore be used for the discovery and evaluation of novel therapeutics for the treatment of this devastating disease.
AB - In order to investigate the antitumor and antimetastatic efficacy of new chemotherapeutic agents, a novel, red-fluorescent, orthotopic model of pancreatic cancer was constructed in nude mice. MIA-PaCa-2 human pancreatic cancer cells were transduced with red fluorescent protein (RFP) and initially grown subcutaneously. Fluorescent tumor fragments were then transplanted onto the pancreas by surgical orthotopic implantation (SOI), facilitating high-resolution, real-time visualization of tumor and metastatic growth and dissemination in vivo. Tumor growth at the primary site was visible within the first postoperative week, while distant metastasis and the development of ascites became visible over the following week. This MIA-PaCa-2-RFP model produced extensive local disease and metastases to the retroperitoneum (100%), spleen (100%), intestinal and periportal lymph nodes (100%), liver (40%) and diaphragm (80%), and gave rise to malignant ascites and peritoneal carcinomatosis in 80% of cases. Growth and metastasis of tumor was more rapid and frequent than in previously described orthotopic pancreatic cancer models, leading to a median survival of only 21 days after tumor implantation. This unique, red fluorescent model rapidly and reliably simulates the highly aggressive course of human pancreatic cancer and can be easily non-invasively visualized in the live animal. The model can therefore be used for the discovery and evaluation of novel therapeutics for the treatment of this devastating disease.
KW - Fluorescence imaging
KW - Metastasis
KW - Pancreatic cancer
KW - Red fluorescent protein
UR - http://www.scopus.com/inward/record.url?scp=1642313625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642313625&partnerID=8YFLogxK
U2 - 10.1023/B:CLIN.0000017160.93812.3b
DO - 10.1023/B:CLIN.0000017160.93812.3b
M3 - Article
C2 - 15065597
AN - SCOPUS:1642313625
SN - 0262-0898
VL - 21
SP - 7
EP - 12
JO - Clinical and Experimental Metastasis
JF - Clinical and Experimental Metastasis
IS - 1
ER -